|
Dec 4
|
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
|
|
Nov 29
|
SpringWorks Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference
|
|
Nov 28
|
SpringWorks Catapults 19% On A 'Watershed Moment' In Cancer Treatment
|
|
Nov 27
|
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
|
|
Nov 2
|
SpringWorks Therapeutics Inc (SWTX) Reports Q3 2023 Financial Results
|
|
Nov 2
|
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
|
|
Nov 1
|
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 CTOS Annual Meeting
|